Factors associated with an achieved response during the first 6 months of receiving a first-line biologic
| Variables | OR (95% CI) | P values |
| Age at initiation of the biologic, >50 years vs ≤50 years | 0.78 (0.21 to 2.92) | 0.72 |
| Female sex | 1.94 (0.52 to 7.17) | 0.32 |
| Associated disease (excl. myelodysplastic syndrome) | 0.93 (0.25 to 3.34) | 0.91 |
| Myelodysplastic syndrome | 0.14 (0.01 to 1.51) | 0.10 |
| Disease duration from diagnosis to receiving a biologic, ≥24 vs <24 months (median) | 0.60 (0.16 to 2.21) | 0.44 |
| Associated non-biologic disease-modifying antirheumatic drug | 2.14 (0.55 to 8.38) | 0.27 |
| Charlson’s score >0 | 0.70 (0.19 to 2.56) | 0.58 |
| Previous manifestations before biologic | ||
| Fever | 0.80 (0.22 to 2.92) | 0.73 |
| Arthralgia/arthritis | 0.64 (0.11 to 3.69) | 0.61 |
| Sternal, sternocostal and sternoclavicular chondritides | 5.00 (1.22 to 20.45) | 0.02 |
| Ophthalmological | 0.44 (0.12 to 1.64) | 0.22 |
| Respiratory tract | 0.69 (0.18 to 2.63) | 0.56 |
| Vestibular and cochlear | 1.06 (0.28 to 4.06) | 0.93 |
| Antibodies | ||
| Rheumatoid factors | 1.58 (0.14 to 17.21) | 0.71 |
| Antinuclear antibodies | 1.68 (0.40 to 7.07) | 0.48 |
| Disease manifestations at onset of a biologic | ||
| Nasal/auricular | 3.64 (0.90 to 14.61) | 0.07 |
| Arthralgia/arthritis | 0.58 (0.14 to 2.34) | 0.44 |
| Sternal, sternocostal and sternoclavicular chondritis | 3.95 (0.90 to 17.40) | 0.07 |
| Ophthalmological | 0.43 (0.09 to 2.09) | 0.29 |
| Respiratory tract | 1.07 (0.29 to 3.92) | 0.92 |
| Vestibular and cochlear | 0.83 (0.17 to 4.14) | 0.82 |
It is a univariate analyses.